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Summary 
For more than a decade, the biological roles and the apparent redundancy of the cytokines tumor 
necrosis factor (TNF) and lymphotoxin (LT) have been debated. LTo~ exists in its soluble form 
as a homotrimer, which like TNF only binds  the  TNF receptors, TNF-R55  or TNF-R75. 
The cell surface form of LT exists as a heteromer of LTot and LT[3 subunits and this complex 
specifically binds  the  LT[3  receptor  (LT[3-R).  To  discriminate  the  functions  of the  LT and 
TNF systems, soluble LT[3-R-immunoglobulin (Ig) or TNF-R-Ig fusion proteins were intro- 
duced into embryonic circulation by injecting pregnant mice. Exposure to LT[3-R-Ig during 
gestation disrupted lymph node development and splenic architecture in the progeny indicating 
that both effects are mediated by the surface LTot/[3 complex. These data are the first to iden- 
tify a cell surface ligand involved in immune organ morphogenesis. Moreover, they unambigu- 
ously discriminate the functions of the various TNF/LT ligands, provide a unique  model to 
study compartmentalization of immune responses and illustrate the generic utility of receptor- 
Ig fusion proteins for dissecting/ordering ontogenetic events in the absence of genetic modifi- 
cations. 
T 
NF,  lymphotoxin  (LT)¥~,  and  LT[3  are  members of 
the TNF superfamily (1). While TNF is expressed by 
many cell types, LToL is basically  restricted to activated lym- 
phocytes. Both molecules can be secreted as homotrimers, 
yet TNF also exists as a cell surface homotrimer retained by 
a  transmembrane  domain.  LTet  (also  called  TNF[3)  and 
TNF homotrimers bind and signal via either of two TNF 
receptors, TNF-R55 or TNF-R75, to mediate host defense 
processes (1, 2). Unlike LTot, LT[3 has not been detected in 
a secreted form nor as a homotfimer, rather, LT[3 as a type II 
integral membrane protein  complexes with  LT0t to  form 
membrane anchored heteromers  (3,  4).  The predominant 
surface LTot/[3 complex does not bind the TNF receptors, 
but does bind to a unique receptor termed the LT[3-R (5). 
Recent reports have shown that recombinant soluble hu- 
man LTe¢/[3  complexes bind LT[3-R to mediate cytolysis 
of a subset of human adenocarcinomas (6) but only ineffi- 
ciently mediate proinflammatory activities (6a). 
In addition to initiating proinflammatory processes, stud- 
ies suggest that TNF and LTo~ can regulate immune func- 
tion  directly  (7,  8).  For example, in  vitro  TNF  signaling 
can affect thymocyte proliferation and differentiation, B  cell 
1Abbrewations used in this paper. GC, germinal centers; LT, lymphotoxln. 
activation  and  prohferation,  and  mixed  lymphocyte  re- 
sponses.  The  direct  involvement of LTot in  the  develop- 
ment/organization of peripheral lymphoid organs was dem- 
onstrated  using  the  targeted  gene  disruption  approach. 
LTot  -/-  mice  lack  LNs  and  Peyer's  patches,  and  their 
spleens have indistinct  follicular marginal zones,  T/B  cell 
disorganization, and fail to form germinal centers (GC) (9- 
11).  Such  effects were  not  noted  in  mice lacking  TNF- 
R75  (12-14). TNF-R55-deficient mice express more lim- 
ited  alterations,  i.e,,  the  absence  of only  Peyer's patches 
(15,  16),  the  failure  to  express  MAdCAM-1  on  splenic 
marginal zone cells, and the inability to form GC (8). Since 
the TNF-R do not appear to mediate the development of 
the  peripheral lymphoid system, it was postulated  that the 
membrane LTod[3/LT[3-R pathway may regulate LN gen- 
esis  (9).  Recently, it has been suggested that lymphotoxin 
mediates "neoorganogensis," a pathologic process mimick- 
ing normal lymph node genesis (17).  Restricted expression 
of LTc~  in  the  pancreas  and  kidney  of transgenic  mice 
caused inflammation in the target tissue manifested by the 
induction of LN-like structures within these organs. 
To investigate the role of LT~x/[3 and TNF in signaling 
immune  system development,  we  used  a  novel  strategy. 
Since human IgGi binds the murine Fc receptor FcRn and 
crosses the yolk sac  (18),  it was considered that introduc- 
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fusion proteins during gestation might interfere with devel- 
opmental processes in the absence of permanent genetic al- 
terations. 
mode. The final images are representative  of these sections. Stain- 
ing of sections  for MAdCAM-1  expression  used  mAb  MECA 
367 (PharMingen)  followed by PE-conlugated goat anti-rat IgG 
(PharMmgen). 
Materials  and Methods 
Animals.  Timed pregnant Balb/c mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME),  housed under con- 
ventional barrier protection, and handled in accordance with in- 
stitutional  guidelines,  tLeceptor-Ig proteins  or mAbs were  in- 
jected i.v. into the tall vein. 
Fusion Proteins and Antibodies.  Fusion proteins comprised of the 
extracellular  domain of either munne LT[3-R or LFA-3 (which 
does  not bind murine CD2)  fused  to the hinge,  CH2, and CH3 
domains of human IgG1 were prepared as described  (19, 20). The 
murine TNF-R55-IgG  1 was created in a similar manner (Brown- 
ing, J., manuscript in preparation).  The absolute  specificity of the 
human receptors for their ligands has been demonstrated in cell- 
based assays (6). In the murine LT system, binding of LT[~-R-Ig 
requires  expression  of both LT& and LT[3 proteins (19). Murine 
LT[3-P,-Ig fusion protein can inhibit the activity  of LTc~/[3 in a 
mouse LT[3-1L-based  cytotoxicity assay in which murine TNF- 
R55-Ig is inactive.  Likewise,  the specificity of the interaction of 
TNF-R55  with  LT&  has  been  well-characterized  in  human 
systems and we have shown further that both human and mouse 
TNF-1L55-Ig can block the activity of recombinant murine LTc~ 
in  a  TNF-1L55-based  cytotoxlcity  assay (Mackay,  F.,  and J. 
Browning,  manuscript  m  preparation).  A  hamster  IgG  mAb 
BBF6  specific  for murine  LT[3 was  prepared  by  conventional 
methodology (Browning, J.,  manuscript  in  preparation).  Anti- 
LT[3 mAb BBF6 can block munne LT~x/[3 signaling in an LT[3- 
R-based cytotoxlcity assay (Mackay,  F., and J. Browning, manu- 
script in preparation).  Polyclonal hamster IgG (PharMmgen, San 
Diego, CA) was used as a control. 
ELISAs.  Analyses for receptor-Is in plasma used mAbs specific 
for munne LT[3-P, (Browning, J., I. Sizmg, P. Lawton, P. Bourdon, 
P. R.ennert,  G. Majeau,  C. Ambrose,  C. Hession, K. Miatkowska, 
D. Grlffiths  et al., manuscript in preparation),  LFA-3 (20), or the 
CH3 domain of human IgG1 (CDG5, prepared at Blogen, Cam- 
bridge, MA) directly immobilized (10 I.zg/ml) on 96-well micro- 
titer plates for capture,  and donkey anti-human IgGl-horseradish 
peroxldase for detection (1:4,000 dilutions; Jackson Immunol~e- 
search Laboratories,  West Grove, PA). ELISA for hamster mAbs 
in plasma  used immobilized goat ann-hamster  IgG  (10  ~g/ml; 
Southern Biotechnology Associates,  Birmingham,  AL)  for cap- 
ture,  and goat anti-hamster IgG-horseradish peroxidase  for detec- 
tion (1:6,000; Southern Bmtechnology Associates). 
Immunohistochemistry.  Tissues were fixed in 10% buffered for- 
malin,  embedded  m  paraffin,  and  sectioned  for  hematoxylin/ 
eosin  staining.  For immunofluorescence staimng,  frozen spleen 
sections were acetone fixed, air dried, and preblocked with 5 I.tg/ml 
ant1-CD16/CD32 Fc block (PharMingen)  in Tris-buffered saline 
with  0.25%  BSA,  0.05%  Tween  20,  and  10%  heat-aggregated 
rabbit  serum.  Ceils were stained  with 5 b~g/rnl blotinylated anti- 
B220 mAb 0PharMingen) in the same buffer, followed by 10 I.~g/ml 
fluorescein  conjugated-neutralite  (FITC-avidin;  Southern  Bio- 
technology Associates)  and  5  b~g/ml PE-conlugated  anti-CD4 
mAb (Pharmingen).  Slides were viewed under X 100 optics  and 
separate red and green images,  digitized.  Each of the images was 
analyzed with  Adobe Photoshop  TM  in a consistent  manner tbl- 
lowed by overlaying of the green and red images  in the screen 
Results  and Discussion 
Gestational  Blockade of L Tc~ / fl Disrupts LN Genesis.  The 
loss of TNF signaling as revealed by the genetic ablation of 
murine TNF-R55 leads to defects in the initiation of acute 
inflammatory cascades,  an inability to defend against intra- 
cellular parasites, failure to generate GC, and the absence of 
Peyer's patches (8,  12-14,  16). In contrast, mice with a dis- 
rupted LT~ gene lack LNs and Peyer's patches, and possess 
spleens  with  indistinct  follicular  marginal  zones  and  T/B 
cell disorganization (9-11). These genetic experiments sug- 
gest  that  disruption  of cell  surface  LTo~/[3  heterommers 
mediates most aspects of the defects in the LTc¢ knockout 
mice. To evaluate the role ofmurine LT~x/[3  complexes in 
the development of the secondary lymphoid organs, the ac- 
tions of surface LT ligand in the fetus and young mice were 
blocked by introducing  either  murine  LTI3-R-Ig or mu- 
fine  TNF-R55-Ig  fusion  proteins,  i.e.,  soluble  receptor 
decoys, into the fetus via maternal transfer or by direct in- 
jection into neonates. 
The  regimen  of fusion  protein  administration  chosen 
was  influenced  by  (a)  the  reported  time  of LN  develop- 
ment during rodent embryogenesis (21);  (b) in situ hybrid- 
ization  studies  showing that  LT[3  mlLNA is  expressed  in 
thymocytes  and  lymph  nodes  (but  not  spleen)  in  mouse 
embryos at  day  16.5  of gestation  (French,  L., J.  Tschopp, 
andJ. Browning, manuscript in preparation);  and (c) obser- 
vations that LT~3-R. message is detected in embryos as early 
as 7  d  after coitus  (22),  and is expressed in some epithelial 
tissues  and  thymus at day  14.5  of gestation  (French,  L., J. 
Tschopp,  and  J.  Browning,  manuscript  in  preparation). 
Thus,  mice were injected i.v.  with  200  b~g of fusion pro- 
tein on days 14 and  17 of gestation,  and the progeny were 
visually inspected for the  presence  of LNs at various ages. 
All LNs and  Peyer's patches  were  readily detected  in  the 
progeny of mice  that  received  either  PBS,  LFA-3-Ig,  or 
TNF-R55-Ig.  In contrast,  inguinal  and popliteal LNs and 
Peyer's patches were absent in the progeny of mice treated 
with  LT[3-1L-Ig  (Table  1).  Microscopic  examination  re- 
vealed the presence of  juxtaposed lymphatic and circulatory 
vessels but no anlage of lymphoid organs at the sites  where 
these nodes are usually observed (Fig.  1). Interestingly, bra- 
chial and  mesenteric  LNs were present  in  the  progeny of 
mice that had been treated with LT[3-1L on days 14 and 17, 
but the former were apparently smaller than those in prog- 
eny  of control-treated  mice.  Since  adult  mice  that  had 
cleared the LT[3-R-Ig still lacked LNs even after immuni- 
zation with antigen in CFA, the interruption  of LT signal- 
lng during fetal development has irreversible  consequences 
for lymph node formation. 
ELISA analyses  showed  that  all  three  IgG  1 fusion  pro- 
teins were present but not at equivalent levels in the circu- 
lation of the progeny (Table 2).  To determine that the effect 
2000  Role of  Lymphotoxin Alpha/Beta in Lymphoid Development Figure 1.  Gestational treatment with LTJ3-R-Ig ablates the formation ofpophteal LNs. Pictures represent the presence or absence ofpopliteat LNs in 
the 22-d-old progeny of pregnant mice that were injected on days 14 and 17 of gestanon with 200 p~g of either LFA-3-Ig (A) or LTJg-tk-Ig (/3). The 
pophteal LN is highlighted by the concentratmn ofin&a mk which was m  lected into the footpad of the mouse 0.5 h before kllhng. 
of LT[3-R  decoy did not merely reflect better maternal- 
fetal transport,  the  dose  of LT[B-R-Ig given  to  pregnant 
mice was titrated. The progeny of mice that received a sin- 
gle i.v. injection of as little as  1  (but not 0.2)  p~g of LT[3- 
R-Ig  on day 14 of gestation, and had a plasma concentra- 
tion below the levels of ELISA detection (10 ng/ml) at 2 d 
of age  lacked popliteal and  inguinal LNs.  Activity of this 
low  dose indicates the  effect of the  LT[B-R-Ig decoy on 
LN  genesis  is  specific  and  not  simply  due  to  achieving 
higher levels of the  former  in  the  fetus.  The  presence  of 
Peyer's  patches  in  TNF-R55-Ig  treated  rmce  (Table  1) 
contrasts to their absence in TNF-R55-deficient mice (16). 
Although repeated administration of the TNF-R55-Ig  has 
m  vivo effects (see the effects of fusion proteins on splenic 
MAdCAM-1  expression below),  and as the TNF-R55-Ig 
serum  level did  not  persist comparably to  that  of LT[B- 
R-Ig  fusion protein in the progeny (Table 2), it is possible 
that TNF-R55-Ig  was not present at sufficient levels to dis- 
rupt development of Peyer's patches which occurs after birth. 
The selective effect of LT[3-R-Ig treatment could result 
from  its  specific engagement  of LTot/[3  complexes  or  its 
binding to  an  undefined  alternative  ligand.  Although  we 
cannot yet ascertain if the endogenous LT~-R  is the medi- 
ating receptor, the role of the LT[3 protein was directly ex- 
amined. LN development was ablated by gestational treat- 
ment with a hamster anti-murine LT~ mAb (Table 1) that 
blocks murine LTex/[3 signaling of munne LT[3-1K in an in 
vitro  assay  (Mackay,  F.,  and J.  Browning,  manuscript  in 
preparation).  The  LN deficmnt phenotype of the LTot -/- 
mice and of mice treated with either LT[3-1K-Ig or murine 
LT[3-specific mAb indicate that the LTcl/[B complex lS re- 
quired to mediate LN genesis during ontogeny. The iden- 
tity of the LTot/[3 + fetal cell type required for LN genesis is 
being investigated. Although LTod[3  is an activation anti- 
gen  restricted in  expression to  T  and  B  lymphocytes and 
NK ceils in adult mice (Browning, J., et al., manuscript sub- 
mitted for publication), the ligand is apparently expressed 
Table 1.  The Development of LNs and Peyer's Patches Is 
Disrupted in the Progeny of Mice Treated with LT~8-specific Reagents 
Number  Spleen 
Treatment  Number  of  Lymph  Peyer's  and 
regime  of litters  progeny  nodes*  patches*  Thymus* 
Receptor-Ig  ¢ 
LTI3-R  15  79  -  -  + 
TNF-R55  4  15  +  +  + 
LFA-3  8  27  +  +  + 
Hamster 
annbodies~ 
LT[3 specxfic  5  21  -  -  + 
Control IgG  3  14  +  +  + 
*A m,nus  sign denotes  the absence and  a plus sign the presence of 
pophteal and inguinal LNs, Peyer's patches, spleens, or thymi as desig- 
nated. Of the 79 mice treated with LT[3-R, none showed any signs of 
possessing popliteal or inguinal nodes. 
Progeny of mice injected l.v. on days 14 and 17 with :~200 lag of solu- 
ble receptor -Ig or 9200 lag of either hamster ann-LT[3 BBF6 or poly- 
clonal hamster IgG were exarmned at vanous ages for the presence or 
absence of lymphmd  organs. Detection of popllteal and ingumal LNs 
was aided by injecting 100 ILl ofm&a ink into rear footpads 2 h before 
examination. 
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Treatment  2-4  7-8 
Days after birth 
14-18  21-24 
lug /ml  lug /ml  lug /mt  lug /ml 
Receptor-Ig 
LTI3-R  31  ±  6.3 (7)  9  +  8 (6) 
TNF-R55  9 +  0.8 (4)  0 (6) 
LFA-3  6  +  1.7 (7)  0.5  --+ 0.25 (2) 
Hamster antibodies 
Anti-LT[3  1.5  +  1 (5)  0.5  +  0.25 (2) 
Control IgG  10 +  4 (4)  7  +  2 (2) 
3.3  +  1.5 (5)  2  +  2 (8) 
ND  ND 
0.01  m 0.02 (5)  0  (2) 
0  (2)  ND 
0.2  (1)  ND 
Progeny of mice that had been injected 1.v. with either 200 I*g of receptor-Ig or 200 tag of hamster antibody on days 14 and 17 of gestation were 
killed on the days indicated. Mean +  SD and sample size (n) represent that of progeny of multiple mothers from multiple experiments. ND, not 
done. 
in the absence of extrinsic  activation on a fetal cell popula- 
tion. 
Ordering of LN Development.  By varying the  gestational 
day of LT[3-R-Ig injection,  the genesis of LNs and Peyer's 
patches was ordered and shown to be as follows: mesenter- 
ics;  brachials;  axillaries;  inguinals  and  pophteals;  Peyer's 
patches  (Table  3).  This  may  reflect  the  extension  of the 
lymphatic  and  circulatory  vasculature  during  murine  on- 
togeny  as  peripheral  LN  development  appears  to  proceed 
in  an  anterior-to-posterior  order.  Interestingly,  mesenteric 
LNs  were  detected  in  the  progeny  of mice  that  had been 
treated  with  LT[3-R-Ig  as  early  as  gestational  day  9,  sug- 
gesting  that  an  additional  LTot-specific  pathway  may  be 
involved  in  the  genesis  of the  mesenteric  nodes.  Alterna- 
tively,  effective  yolk  sac  transport  may  not  occur  early 
enough  during  development  to  ablate  the  formation  of 
these nodes. Together with the inability to detect an empty 
anlage,  these data indicate that LT[3-R-Ig binds its specific 
hgand to influence the development of LNs rather than  to 
obliterate  LNs  already  established  during  embryogenesis. 
Ongoing studies that do not show the gross deletion of the 
LN  anlage  in  normal  adult  mice  treated  with  LT[3-R-Ig 
(Mackay,  F.,  and J.  Browmng,  manuscript  in  preparation) 
or  in  mice  expressing  an  LT[3-R-Ig  transgene  after  birth 
(22a)  also suggest that the effect of LT[3-R-Ig on LN gen- 
esis  has  a  specific  temporal  requirement  corresponding  to 
the time of LN formation during ontogeny. 
Blockade of LTa/~ Alters Splenic Architecture.  The  pres- 
ence  of the  thymus  and  spleen  in  the  progeny  of LT[3- 
R-Ig-treated mice and in LTc~ -/-  mice shows that LTc~/[3 
Table 3.  L T/3-R-Ig Treatment Orders the Development of Peripheral Lymphoid Organs 
Lymph nodes* 
Gestational  Peyer's 
day treated*  Mesenteric  Brachial  Axrllary  Inguinal  Popliteal  patches*  Spleen* 
9  +  ....  ND  + 
10  +  ....  ND  + 
11  +  ....  ND  + 
12  +  ....  ND  + 
13  +  +  -  -  -  ND  + 
14  +  +  -  -  -  ND  + 
15  +  +  +  -  -  ND  + 
16  +  +  +  +  -  ND  + 
I7  +  +  +  +  +  -  + 
18  +  +  +  +  +  -  + 
*  Plus sign indicates that lymphoid organ is present; minus sign indicates its absence. 
*Pregnant mice were injected i.v. with 100  btg LT~-R-Ig on indicated day of gestation. SLx or more progeny were evaluated for the presence of 
secondary lymphmd organs. 
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Figure  2.  Effects of LTct/[3 inhibition on splenic architecture.  (Top)  Hematoxyhn/eosm staining of spleens of mice treated m  utero and posmatally 
with a (A) control protein LFA-3-Ig or (B) LT[3-R-Ig. Pregnant mice were m lected i.v. vclth 200 ~g of soluble receptor on days 14 and 18 of gestation. 
Pups were then injected i.p. on 7,  14, 21, and 28 d  after birth and their spleens were analyzed at 5 wk. (Bottom) Companson of the dlsruptmn of the T 
and B  cell spleen zones m  the LT~x  -/- mice with those of the progeny of mice rejected with LTJ3-R-Ig. Frozen spleen sections were stained for CD4 + 
T  cells (red) or B220 + B  cells (green). Yellow color shows overlapping staining.  Shown are spleen sections from (C)  an adult LTct +/+ mouse,  (D) an 
LTct -/- mouse, (E) a 5-wk-old mouse whose mother was rejected with 200 ~g of LT[3-R-Ig on days 14 and 17 of gestation, and (F) a 5-wk-old mouse 
derived as per E but with continued in3ectlons 1.p. at 7,  14, 21 and 28 d after birth. 
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Figure 3.  Expression of MAdCAM-1  on splenic marginal zone cells. 
MAdCAM-1  expression on splenic marginal zone cells of progeny de- 
rived from pregnant rmce treated 1.v. (A) on days 14 and 17 of gestation 
with 200 p~g of LFA-3-Ig (control),  (B)  on days 14 and 17 of gestauon 
with 200 p~g of LT[3-1K-Ig  followed by i p. rejections on days 7, 14, 21, 
and 28 after birth with LFA-3-Ig, and (C) as per B but all rejections were 
with LT~3-R-Ig. Each digital linage was processed m an identical manner. 
engagement  is  not  required  for  their  morphogenesis.  To 
probe for more subde  effects, histological  examinations  of 
the spleens and thymi from treated and control mice were 
performed. As the spleen is populated with lymphocytes in 
the  weeks  after  birth,  injections  of soluble  LT[3-1K-Ig- 
treated progeny were  continued  posmatally (100  p,g once 
weekly for 5 wk).  Histological analyses showed that thymi 
had  clearly defined  cortical  and  medullary zones  (data not 
shown)  and that both red and white pulp  components  are 
detected  in  the  spleens  of LT[3-R-Ig  mice  treated  only 
during  fetal  development.  However,  after  multiple  LT[3- 
1K-Ig injections  the  red  and  white  pulp  became  disorga- 
nized  (Fig.  2, A  and B) as in LTot -/-  mice (9,  10).  More- 
over, immunohistochemical  analyses showed alterations  in 
lymphocyte  positioning  in  the  white  pulp.  Although  T 
cells still appeared to concentrate  around the central arteri- 
oles, these periarteriolar lymphoid sheaths were reduced in 
size, the B  cells follicles had ragged edges, and T  and B cells 
failed to segregate exclusively into these zones (Fig. 2  F) as 
in spleens of control mice (Fig. 2  C). Such lymphocyte dis- 
organization was observed in LTot  -/-  (Fig. 2 D, and 9,  11) 
but not in TNF-R55 -/-  mice (8). 
Marginal  zone  cells  bounding  the  T/B  regions  of the 
spleens  from  LTot -/-  mice  fail  to  express  a  characteristic 
marker, MOMA-1  (8).  In our system, the expression of yet 
another  marginal  zone  marker,  MAdCAM-1,  was lacking 
in  spleens  of mice treated  multiple  times  with  LTJ3-R-Ig 
(Fig.  3  C)  or TNF-R55-Ig  (data  not  shown).  Similar  ef- 
fects of LTJ3-R-Ig but not TNF-R55-Ig  on expression of 
other  marginal  zone  markers  (i.e.,  sialoadhesin)  were  also 
noted  (data not shown).  When LT[3-R-Ig was introduced 
only during gestation,  relatively minor T  and B  cell disor- 
ganization  was noted  (Fig.  2  E), yet marginal zone MAd- 
CAM-1  expression was diminished  (Fig.  3  B)  and the  size 
of white pulp islands appears to be reduced (data not shown). 
This apparent continuum of LTf3-R-Ig splenic effects sug- 
gests that continuous interaction of LTcx/[3 with LTJ3-R or 
an  alternative  receptor influences  the  organization  of cells 
in this secondary lymphoid organ. 
In  this  work,  we  have  reproduced  most  aspects  of the 
phenotype  of the  LToL -/-  mouse  (except  the  absence  of 
mesenteric LNs) by administering sohible LT[3-R-Ig, thus 
showing  that  membrane  LTot/J3  and  not  LTot3  signals  a 
specific molecular pathway which  controls LN genesis,  or- 
ganization  of lymphocytes within  splenic  follicles,  and  the 
integrity of the splenic marginal zone.  It will be interesting 
to  determine  whether  LTot/[3  acts  as  a  master switch  di- 
recting  the  expression  of cell  surface  markers  (i.e.,  MAd- 
CAM-1  or MOMA-1)  essential to these processes or con- 
trolling  other  activities  of as yet undefined  organizing  cell 
types.  TNF-R55 -/-  mice  express  MOMA-1  (8)  but  not 
MAdCAM-1  (23) in the splenic marginal zones, suggesting 
that  MAdCAM-1  expression  on  marginal  zone  cells  does 
not  directly  correlate  with  lymphocyte  disorganization  xn 
the white pulp. Our data also show reasonable T/B organi- 
zation when MAdCAM-1  expression is reduced  (Figs.  2  E 
and 3  B) thus questioning the requirement of this adhesion 
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experiments  using toxic liposomes to eliminate MOMA-1 + 
splenic macrophages also did not show splenic disorganiza- 
tion  (24).  The  failure  of mutant  aly  mice  (25,  26),  relB- 
deficient mice (27, 28), and Ikaros knockout mice (29) to 
develop LNs and the disorganized lymphoid architecture in 
the spleen  of the aly (26)  and relB-deficient mice  (27,  28) 
designates  roles  for  other  components  in  these  processes. 
However, our data show that expression of the LT[3 gene, 
like  the  Hox11  gene  which  controls  the  genesis  of the 
spleen  (30),  has  a  central  role  in  the  development  of the 
secondary lymphoid organs in the absence of the immuno- 
compromised phenotype noted m  the aly mice,  relB,  and 
Ikaros-deficient  mice.  Moreover,  LTcx/[3  is  distinct  from 
these transcription factors, representing the first cell surface 
ligand identified to be critical for such immune morphoge- 
netic processes. 
LT[3-R is expressed on reticular dendritic cells in the red 
pulp of human fetal spleen (30a)  and has not been found on 
T  or B  lymphocytes.  Surface  ligand  in  contrast  has  been 
observed  only on activated  human  T  and  B  lymphocytes 
and  NK  cells  (31).  Contact  between  trafficking/activated 
LTot/I3 +  lymphocytes and  stromal  elements  such  as  den- 
dritic  cells  in  peripheral  lymphoid  organs  could  facilitate 
the  subsequent  positiomng of lymphocytes as in GC forma- 
tion and thus influence  the  maturation  of the  immune  re- 
sponse.  The  absence  of such  a  signal  would  result  in  the 
splenic phenotype and impaired GC formation observed in 
the LTot knockout mice (8).  As the LTci  -/- mice manifest 
an LTot/[3-  phenotype,  the role of LToL/[3  in GC forma- 
tion is under study using the tools described herein.  Such a 
role  for membrane  LT is also  consistent with reports  that 
TNF superfamily members participate in cognate interactions 
(31, 32).  Impairment  of CD40/CD40L  interactions  causes 
profound  immunodeficiency  (33),  and  disruption  of either 
the  CD40/CD40L  interaction  or  the  TNF-P,.55  or  LTci 
genes contributes to the failure to form GC (38). As CD40 
ligation induces expression of LTot/[3 complexes on B  cells 
(35,  and Hochman, P.,  unpublished  data),  CD40 and sur- 
face LT may represent steps in a linear sequence of events. 
Alternatively,  since both  CD40 and LT[3-R share  a  cyto- 
plasmic  signal  transduction  element,  TRAF-3  (36),  these 
pathways may have interdependent  roles in the formanon 
and maintenance of GC. 
Finally, this report documents a technique that disrupts a 
discrete  developmental  pathway without  the  need for ge- 
netic manipulation.  Taken together with the Hox11 knock- 
out  (30),  this  strategy  can  generate  powerful  models  to 
evaluate  the  compartmentahzation  of the  immune  system. 
Since soluble receptors can be introduced at specific points 
in ontogeny, the approach shown herein  can order devel- 
opmental events and facilitate the study of multifunctional 
pathways where genetic disruption  has led to a lethal phe- 
notype, as in the case of ablation of the oL4 integrin gene (37). 
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